Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With Rivaroxaban
- 1 March 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 44 (3), 771-778
- https://doi.org/10.1161/strokeaha.112.675231
Abstract
Background and Purpose—: Rivaroxaban has recently been approved for stroke prevention in atrial fibrillation. However, lack of an effective antidote represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model of ICH associated with rivaroxaban, and to examine the effectiveness of different hemostatic factors in preventing excess hematoma expansion. Methods—: In C57BL/6 mice receiving 10 or 30 mg/kg rivaroxaban by gastric gavage, plasma concentration, prothrombin time, and coagulation factor activities were measured repeatedly. Thirty minutes after inducing ICH by intrastriatal collagenase-injection, mice received an intravenous injection of either saline, prothrombin complex concentrate (100 U/kg), murine fresh frozen plasma (200 μL), or recombinant human Factor VIIa (1 mg/kg). ICH volume was quantified on brain cryosections and using hemoglobin spectrophotometry 24 hours later. Results—: Rivaroxaban in 30 mg/kg dose substantially increased the hematoma volume in ICH induced by 0.060 U collagenase. Prothrombin complex concentrate, fresh frozen plasma, or Factor VIIa prevented excess hematoma expansion caused by anticoagulation. Prevention of hematoma expansion by prothrombin complex concentrate was dose-dependent. None of the 3 agents completely corrected the prolonged prothrombin time, although they restored the activities of deficient FII and X. Conclusions—: Prothrombin complex concentrate, Factor VIIa, and fresh frozen plasma prevent excess intracerebral hematoma expansion in a murine ICH model associated with rivaroxaban. The efficacy and safety of this reversal strategy must be further evaluated in clinical studies.Keywords
This publication has 33 references indexed in Scilit:
- Letter by Marlu et al Regarding Article, “Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects”Circulation, 2012
- Determination of Rivaroxaban in Human Plasma SamplesSeminars in Thrombosis and Hemostasis, 2012
- Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor DabigatranStroke, 2011
- Comparative Effectiveness of Hemostatic Therapy in Experimental Warfarin-Associated Intracerebral HemorrhageStroke, 2011
- Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitorBritish Journal of Clinical Pharmacology, 2010
- New AnticoagulantsCirculation, 2010
- Experimental Model of Warfarin-Associated Intracerebral HemorrhageStroke, 2008
- Warfarin use leads to larger intracerebral hematomasNeurology, 2008
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesAmerican Journal Of Medicine, 2007
- Experimental Intracerebral Hemorrhage in the MouseStroke, 2003